GLAND · Healthcare
Gland Pharma Ltd. reported revenue of ₹1,074 cr for July to September 2025, — on the year and — on the quarter.
Operating profit (EBITDA) was ₹375 cr, a margin of 34.9%, — on the year and — on the quarter.
Net profit was ₹302 cr, — on the year and — on the quarter, with earnings per share of ₹18.33.
Pharma quarters swing with US generic launches and price erosion, while India formulations grow more steadily. Currency gains and other income can be material, so headline profit needs a check against operating profit. The quarterly statements do not carry the US and India split, R&D spend and any FDA observations; those come with the filing read.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Metric | Q2 FY26 |
|---|---|
| US revenue ($ m) | 827.9 |
| R&D, % of sales | 5% |
| Gross margin | 62.76% |
Read using the Pharmaceuticals framework (named in the filing read). Primary valuation lens: P/E excluding one-time exclusivity gains.
Read more closely in this sector: Status of each US-filed plant · Price erosion stated · One-product dependence.
| Q2 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|
| Revenue | ₹1,074 cr | ₹1,287 cr | ₹1,402 cr |
| YoY | — | — | +31% |
| EBITDA margin | 34.9% | 36.8% | 39.1% |
| Other income, % of PBT | 20% | 12% | 13% |
| Exceptional items | — | — | — |
| Tax rate | 26% | 25% | 26% |
| Net profit | ₹302 cr | ₹364 cr | ₹425 cr |
| YoY | — | — | +41% |
| Core profit YoY | — | — | +53% |
| EPS | ₹18.33 | ₹22.11 | ₹25.75 |
| Flags | · | · | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Gland Pharma Ltd. reported revenue of ₹1,074 cr (— on the year) and net profit of ₹302 cr (— on the year) for July to September 2025.
None of the 2 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.